Cargando…

Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides

The addictive nature of nicotine is likely the most significant reason for the continued prevalence of tobacco smoking despite the widespread reports of its negative health effects. Nicotine vaccines are an alternative to the currently available smoking cessation treatments, which have limited effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Hoang-Thanh, Fraleigh, Nya L., Lewicky, Jordan D., Boudreau, Justin, Dolinar, Paul, Bhardwaj, Nitin, Diaz-Mitoma, Francisco, Montaut, Sabine, Fallahi, Sarah, Martel, Alexandrine L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143940/
https://www.ncbi.nlm.nih.gov/pubmed/32178357
http://dx.doi.org/10.3390/molecules25061290
_version_ 1783519732381515776
author Le, Hoang-Thanh
Fraleigh, Nya L.
Lewicky, Jordan D.
Boudreau, Justin
Dolinar, Paul
Bhardwaj, Nitin
Diaz-Mitoma, Francisco
Montaut, Sabine
Fallahi, Sarah
Martel, Alexandrine L.
author_facet Le, Hoang-Thanh
Fraleigh, Nya L.
Lewicky, Jordan D.
Boudreau, Justin
Dolinar, Paul
Bhardwaj, Nitin
Diaz-Mitoma, Francisco
Montaut, Sabine
Fallahi, Sarah
Martel, Alexandrine L.
author_sort Le, Hoang-Thanh
collection PubMed
description The addictive nature of nicotine is likely the most significant reason for the continued prevalence of tobacco smoking despite the widespread reports of its negative health effects. Nicotine vaccines are an alternative to the currently available smoking cessation treatments, which have limited efficacy. However, the nicotine hapten is non-immunogenic, and successful vaccine formulations to treat nicotine addiction require both effective adjuvants and delivery systems. The immunomodulatory properties of short, non-natural peptide sequences not found in human systems and their ability to improve vaccine efficacy continue to be reported. The aim of this study was to determine if small “non-natural peptides,” as part of a conjugate nicotine vaccine, could improve immune responses. Four peptides were synthesized via solid phase methodology, purified, and characterized. Ex vivo plasma stability studies using RP-HPLC confirmed that the peptides were not subject to proteolytic degradation. The peptides were formulated into conjugate nicotine vaccine candidates along with a bacterial derived adjuvant vaccine delivery system and chitosan as a stabilizing compound. Formulations were tested in vitro in a dendritic cell line to determine the combination that would elicit the greatest 1L-1β response using ELISAs. Three of the peptides were able to enhance the cytokine response above that induced by the adjuvant delivery system alone. In vivo vaccination studies in BALB/c mice demonstrated that the best immune response, as measured by nicotine-specific antibody levels, was elicited from the conjugate vaccine structure, which included the peptide, as well as the other components. Isotype analyses highlighted that the peptide was able to shift immune response toward being more humorally dominant. Overall, the results have implications for the use of non-natural peptides as adjuvants not only for the development of a nicotine vaccine but also for use with other addictive substances and conventional vaccination targets as well.
format Online
Article
Text
id pubmed-7143940
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71439402020-04-13 Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides Le, Hoang-Thanh Fraleigh, Nya L. Lewicky, Jordan D. Boudreau, Justin Dolinar, Paul Bhardwaj, Nitin Diaz-Mitoma, Francisco Montaut, Sabine Fallahi, Sarah Martel, Alexandrine L. Molecules Article The addictive nature of nicotine is likely the most significant reason for the continued prevalence of tobacco smoking despite the widespread reports of its negative health effects. Nicotine vaccines are an alternative to the currently available smoking cessation treatments, which have limited efficacy. However, the nicotine hapten is non-immunogenic, and successful vaccine formulations to treat nicotine addiction require both effective adjuvants and delivery systems. The immunomodulatory properties of short, non-natural peptide sequences not found in human systems and their ability to improve vaccine efficacy continue to be reported. The aim of this study was to determine if small “non-natural peptides,” as part of a conjugate nicotine vaccine, could improve immune responses. Four peptides were synthesized via solid phase methodology, purified, and characterized. Ex vivo plasma stability studies using RP-HPLC confirmed that the peptides were not subject to proteolytic degradation. The peptides were formulated into conjugate nicotine vaccine candidates along with a bacterial derived adjuvant vaccine delivery system and chitosan as a stabilizing compound. Formulations were tested in vitro in a dendritic cell line to determine the combination that would elicit the greatest 1L-1β response using ELISAs. Three of the peptides were able to enhance the cytokine response above that induced by the adjuvant delivery system alone. In vivo vaccination studies in BALB/c mice demonstrated that the best immune response, as measured by nicotine-specific antibody levels, was elicited from the conjugate vaccine structure, which included the peptide, as well as the other components. Isotype analyses highlighted that the peptide was able to shift immune response toward being more humorally dominant. Overall, the results have implications for the use of non-natural peptides as adjuvants not only for the development of a nicotine vaccine but also for use with other addictive substances and conventional vaccination targets as well. MDPI 2020-03-12 /pmc/articles/PMC7143940/ /pubmed/32178357 http://dx.doi.org/10.3390/molecules25061290 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Le, Hoang-Thanh
Fraleigh, Nya L.
Lewicky, Jordan D.
Boudreau, Justin
Dolinar, Paul
Bhardwaj, Nitin
Diaz-Mitoma, Francisco
Montaut, Sabine
Fallahi, Sarah
Martel, Alexandrine L.
Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides
title Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides
title_full Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides
title_fullStr Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides
title_full_unstemmed Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides
title_short Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides
title_sort enhancing the immune response of a nicotine vaccine with synthetic small “non-natural” peptides
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7143940/
https://www.ncbi.nlm.nih.gov/pubmed/32178357
http://dx.doi.org/10.3390/molecules25061290
work_keys_str_mv AT lehoangthanh enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT fraleighnyal enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT lewickyjordand enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT boudreaujustin enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT dolinarpaul enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT bhardwajnitin enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT diazmitomafrancisco enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT montautsabine enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT fallahisarah enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides
AT martelalexandrinel enhancingtheimmuneresponseofanicotinevaccinewithsyntheticsmallnonnaturalpeptides